10-Q: Third Harmonic Bio Reports Second Quarter 2024 Financial Results, Advances THB335 Clinical Program

Third Harmonic Bio's second quarter 2024 results show increased R&D spending as the company advances its lead drug candidate, THB335, into clinical trials.

Summary

• Third Harmonic Bio, a clinical-stage biopharmaceutical company, reported a net loss of $10.7 million for the three months ended June 30, 2024, and $18.6 million for the six months ended June 30, 2024.
• The company's research and development expenses increased to $8.4 million for the three months ended June 30, 2024, and $14.6 million for the six months ended June 30, 2024, primarily due to the advancement of the THB335 program.
• General and administrative expenses were $5.7 million for the three months ended June 30, 2024, and $10.7 million for the six months ended June 30, 2024.
• As of June 30, 2024, Third Harmonic Bio had $255.3 million in cash and cash equivalents, which they believe will be sufficient to fund operations through at least 2026.
• The company initiated a Phase 1 clinical trial for THB335, with clinical results expected in the first quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in advancing its lead drug candidate and has sufficient cash, it is also experiencing significant losses and has identified a material weakness in its internal controls. The increased R&D spending is a positive sign for future development, but the lack of revenue and the inherent risks of drug development temper the overall outlook.

Positives

• The company has sufficient cash to fund operations through at least 2026.
• The Phase 1 clinical trial for THB335 has commenced.
• THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk as well as provide a differentiated metabolic, distribution and physiochemical profile.

Negatives

• The company has incurred significant net losses since inception and expects to continue to incur losses.
• There is a material weakness in the company's internal control over financial reporting.
• The company has a limited operating history and has not completed any clinical trials beyond Phase 1.
• The company has not generated any revenue from product sales.

Risks

• The company's future performance is substantially dependent on the success of THB335 and its ability to develop future product candidates.
• Drug development is a lengthy and expensive process with uncertain outcomes.
• Clinical trials may reveal significant adverse events not seen in nonclinical studies.
• The company faces competition from other entities developing treatments for allergic and inflammatory diseases.
• The company relies on third parties to conduct clinical trials and perform research.
• The company may not be able to obtain, maintain, and enforce patent protection for its technologies.
• The regulatory approval process is highly uncertain, and the company may be unable to obtain regulatory approval.
• The company may be subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.
• Adverse developments affecting the financial services industry could negatively impact the company's operations.

Future Outlook

The company expects to report clinical results from the Phase 1 trial of THB335 during the first quarter of 2025 and plans to follow with a Phase 2 trial in CSU and expansion into other mast cell-mediated disorders. The company believes its existing cash and cash equivalents will be sufficient to fund operations through at least 2026.

Management Comments

• The company is leveraging its nonclinical and clinical experience with THB001 to prioritize speed to Phase 2 with THB335.
• The company believes its current manufacturers are able to supply the upcoming clinical trials and additional CDMOs may be on-boarded at later stages of clinical and commercial development.

Industry Context

The company is operating in a competitive biopharmaceutical landscape with numerous companies developing treatments for allergic and inflammatory diseases. The company is focused on developing oral KIT inhibitors, a relatively new approach in this field.

Comparison to Industry Standards

• The company's focus on oral KIT inhibitors places it in competition with companies like Celldex (barzolvolimab) and Incyte (EP262), which are also developing treatments for mast cell-mediated diseases.
• The company's reported cash position of $255.3 million is relatively strong for a clinical-stage biotech company, but its burn rate is also high due to increased R&D spending.
• The company's decision to discontinue the THB001 trial due to liver transaminitis highlights the risks inherent in drug development, a common challenge in the industry.
• The company's timeline for Phase 1 results in Q1 2025 is typical for early-stage clinical trials, but the overall development timeline remains uncertain.

Related Party Transactions

• Novartis is a significant beneficial owner of the company and has an in-license agreement with the company.
• The company entered into a Promissory Note with the CEO, which was later forgiven, and the CEO was paid a one-time special bonus to offset the tax liability.

Stakeholder Impact

• Shareholders face the risk of continued losses and potential dilution from future capital raises.
• Employees may benefit from the company's growth and development efforts.
• Patients may benefit from the development of new treatments for mast cell-mediated diseases.
• Suppliers and creditors may benefit from the company's ongoing operations and spending.

Next Steps

• The company will continue the Phase 1 clinical trial of THB335.
• The company plans to initiate a Phase 2 trial in CSU following the Phase 1 trial.
• The company will continue to conduct reproductive and chronic toxicology studies to support rapid advancement toward late-stage clinical development.

Key Dates

Keywords

THB335, KIT inhibitor, clinical trial, biopharmaceutical, mast cell, urticaria, inflammatory diseases, research and development, regulatory approval, financial results